|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,285.35 INR | +0.09% |
|
+3.16% | +8.21% |
| 05-08 | Lupin Limited, Q4 2026 Earnings Call, May 08, 2026 | |
| 05-08 | Lupin's Consolidated Profit Rises in Fiscal Q4 | MT |
Business description: Lupin Limited
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Number of employees: 24,006
Sales by Activity: Lupin Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
Pharmaceuticals | 152B | 164B | 166B | 200B | 226B |
Others | - | - | - | - | 1.05B |
Inter Segment Revenue | - | - | - | - | -18.6M |
Geographical breakdown of sales: Lupin Limited
| Fiscal Period: March | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) |
|---|---|---|---|---|---|
India | 59.32B | 64.6B | 66.51B | 73.17B | 85.05B |
USA | 54.02B | 56.35B | 51.58B | 71.05B | 77.24B |
Others | 36.02B | 43.11B | 48.33B | 55.89B | 64.79B |
Japan | 2.27B | - | - | - | - |
Executive Committee: Lupin Limited
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 31/08/2013 | |
| Director of Finance/CFO | 61 | 12/08/2007 | |
Amit Kumar Gupta
CMP | Compliance Officer | - | 31/08/2024 |
Christoph Funke
CTO | Chief Tech/Sci/R&D Officer | - | 17/03/2024 |
Shahin Fesharaki
CTO | Chief Tech/Sci/R&D Officer | - | - |
Composition of the Board of Directors: Lupin Limited
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 52 | 07/10/2008 | |
| Director/Board Member | 58 | 31/12/1996 | |
| Chairman | 82 | 10/08/2017 | |
| Director/Board Member | 61 | - | |
Mark McDade
BRD | Director/Board Member | 71 | 27/01/2021 |
| Director/Board Member | 60 | 11/08/2020 | |
Alfonso Zulueta
BRD | Director/Board Member | 63 | 05/05/2024 |
Jeffrey Kindler
BRD | Director/Board Member | 70 | 05/05/2024 |
Punita Lal
BRD | Director/Board Member | 62 | 13/05/2025 |
| Director/Board Member | 67 | 31/01/2026 |
Company details: Lupin Limited
Group companies: Lupin Limited
| Name | Category and Sector |
|---|---|
Lupin Atlantis Holdings SA
 Lupin Atlantis Holdings SA Pharmaceuticals: MajorHealth Technology Operates as a holding company which manufactures and distributes pharmaceutical products |
Pharmaceuticals: Major
|
Lupin Atlantis Holdings SA
Lupin Atlantis Holdings SA Pharmaceuticals: MajorHealth Technology Operates as a holding company which manufactures and distributes pharmaceutical products |
Pharmaceuticals: Major
|
Nanomi BV
 Nanomi BV Pharmaceuticals: MajorHealth Technology Manufactures and develops medicines |
Pharmaceuticals: Major
|
Nanomi BV
Nanomi BV Pharmaceuticals: MajorHealth Technology Manufactures and develops medicines |
Pharmaceuticals: Major
|
Generic Health Pty Ltd.
 Generic Health Pty Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical products |
Pharmaceuticals: Major
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.09% | +3.16% | +16.31% | +195.19% | 10.81B | |
| +1.81% | +3.35% | +43.52% | +139.74% | 909B | |
| +0.12% | -0.52% | +49.89% | +46.36% | 552B | |
| +0.91% | +1.74% | +17.95% | +47.98% | 375B | |
| +0.59% | +2.53% | +24.56% | +13.82% | 332B | |
| +0.40% | +1.94% | +33.49% | +16.37% | 291B | |
| +0.59% | +2.19% | +27.18% | +30.69% | 287B | |
| +1.27% | +0.96% | +48.74% | +0.01% | 279B | |
| -1.47% | -0.65% | -37.77% | -51.83% | 199B | |
| +0.90% | -0.23% | +23.63% | +49.76% | 179B | |
| Average | +0.56% | +0.97% | +24.75% | +48.81% | 341.39B | |
| Weighted average by Cap. | +0.82% | +1.04% | +32.23% | +55.49% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 500257 Stock
- Company Lupin Limited
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition